Work

Aseptic meningoencephalitis during nusinersen therapy in a patient with type III spinal muscular atrophy: a case report

Year: 2025

Type: article

Abstract: Nusinersen, an intrathecally-administered antisense oligonucleotide for the treatment of spinal muscular atrophy (SMA), may rarely cause mild aseptic meningitis early in treatment. We report a severe late-onset aseptic brain stem meningoencephalitis in a 42-year-old man with type III SMA, occurring 38 months after starting nusinersen. The patient showed clinical and radiological signs of brain stem meningoencephalitis with significant CSF neutrophilic pleocytosis, despite negative infectious disease tests. After high-dose steroids and tapering, symptoms and imaging findings resolved. This case suggests a potential link between nusinersen and aseptic meningoencephalitis in adult SMA, extending previous reports of rare drug-induced aseptic meningitis. Physicians should consider this as a possible adverse event in patients undergoing intrathecal nusinersen therapy.

Source: Repository for Publications and Research Data (ETH Zurich)

DOI: 10.3929/ethz-b-000734445

Authors: Kolakowski, Lukasz, Zschau, Olivia, Bonzon, Jérôme, De Vere-Tyndall, Anthony, Herwerth, Marina, Neuwirth, Christoph, Weller, Michael, Roth, Patrick, Schreiner, Bettina, Kana, Veronika

Language: English

Topic: Neurogenetic and Muscular Disorders Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W6909811059

FWCI:

Cites:

Cited by:

Related to: